RxDoctor Payments Data

Marina Sobol, MD

Neurology · Edison, NJNPI 1841344694

Payments from drug & device makers

$68,569in general payments, 2019–2025

Across 370 payments — averaging $185.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$49K
  • Biohaven Pharmaceuticals, Inc.$13K
  • Biohaven Pharmaceutical Holding Company Ltd.$2K
  • Teva Pharmaceuticals USA, Inc.$996
  • Lilly USA, LLC$810
  • Neurocrine Biosciences, Inc.$410
  • plus $2K from 28 others

What the payments were for

  • Speaking & faculty fees$60,37588%
  • Travel & lodging$4501%
  • Food & beverage$7,61511%
  • Education$1290%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$68,569 in reported general payments places this provider in the 85th percentile of 521 neurology providers in New Jersey.

See all neurology providers in New Jersey

Medicare billing

Part B allowed, 2024
$82,416
Medicare patients
67
Services billed
4,381

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
UbrelvyUbrogepant42$67,136
QuliptaAtogepant28$29,242
BotoxOnabotulinumtoxina21$27,262
Aimovig AutoinjectorErenumab-Aooe26$24,365
Emgality PenGalcanezumab-Gnlm28$22,992
Nurtec OdtRimegepant Sulfate11$22,880
Ajovy AutoinjectorFremanezumab-Vfrm18$13,628
Carbidopa-Levodopa-EntacaponeCarbidopa/Levodopa/Entacapone11$6,813
Gabapentin121$3,781
Memantine Hcl ErMemantine Hcl18$3,289
Memantine Hcl61$1,524
Tizanidine Hcl38$1,090
RizatriptanRizatriptan Benzoate19$950
Duloxetine Hcl53$819
Amitriptyline Hcl72$802

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy, Qulipta, Botox$48,662$123,64191 claims
PfizerNurtec Odt$32$22,88011 claims
Upsher-smith Laboratories LLCTopiramate$46$64238 claims
Almatica Pharma LLCSertraline Hcl$12$35619 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 521 neurology providers in New Jersey.

Other neurology in Edison

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →